Functional Esophageal Disorders.
Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, Zerbib F.
Gastroenterology. 2016 Feb 15:S0016-5085(16)00178-5. doi: 10.1053/j.gastro.2016.02.012. Online ahead of print.
Minimally Invasive Resection for Oncologically Borderline Distant Lymph Node Metastasis in Esophageal Cancer: Is This Extended or Less-Invasive Surgery?
Motoyama S.
Ann Surg Oncol. 2024 Mar;31(3):1438-1439. doi: 10.1245/s10434-023-14720-9. Epub 2023 Dec 8.
Clinical outcomes of conversion surgery after induction immunochemotherapy for borderline resectable T4 esophageal squamous cell carcinoma.
Zhang C, Xu B, Luo T, Zhang Y, Zhang L, Shi G, Fu M.
World J Surg Oncol. 2024 Nov 1;22(1):288. doi: 10.1186/s12957-024-03570-8.
Preoperative neoadjuvant chemoradiotherapy provides borderline resectable thoracic esophageal cancer with equivalent treatment results as clinically T3 thoracic esophageal cancer.
Wakita A, Motoyama S, Sato Y, Nagaki Y, Fujita H, Kemuriyama K, Hayashi K, Imai K, Nanjo H, Minamiya Y.
Ann Gastroenterol Surg. 2023 Jun 11;7(6):904-912. doi: 10.1002/ags3.12706. eCollection 2023 Nov.
Assessment of changes in tumor heterogeneity following neoadjuvant chemotherapy in primary esophageal cancer.
Yip C, Davnall F, Kozarski R, Landau DB, Cook GJ, Ross P, Mason R, Goh V.
Dis Esophagus. 2015 Feb-Mar;28(2):172-9. doi: 10.1111/dote.12170. Epub 2014 Jan 27.
Preoperative camrelizumab combined with chemotherapy for borderline resectable ESCC: A single-arm, prospective, phase 2 study.
Zhang G, Mu T, Zhang Y, Jiao J, Ding Z, Yang H, Pan D, Zhao J, Li J, Li X.
Med. 2024 Nov 8;5(11):1424-1432.e3. doi: 10.1016/j.medj.2024.07.015. Epub 2024 Aug 8.
Radiotherapy in the management of rare gastrointestinal cancers: A systematic review.
Bellefkih FZ, Benchakroun N, Lalya I, Amaoui B, El Kacemi H, Acharki A, El Hfid M, El Mazghi A, Chekrine T, Bouchbika Z, Jouhadi H, Sahraoui S, Tawfiq N, Michalet M.
Cancer Radiother. 2023 Sep;27(6-7):622-637. doi: 10.1016/j.canrad.2023.06.010. Epub 2023 Jul 25.
Neoadjuvant Chemoradiotherapy Followed by Minimally Invasive Esophagectomy for Borderline Resectable Esophageal Squamous Cell Carcinoma.
Hosogi H, Yoshida S, Sakaguchi M, Kanaya S.
J Gastrointest Surg. 2023 Dec;27(12):3040-3042. doi: 10.1007/s11605-023-05876-6. Epub 2023 Nov 2.
Paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced borderline-resectable esophageal squamous cell carcinoma: a phase II clinical trial.
Wang Z, Hu M, Hu Y, Li Q, Wu J, Fong WP, Ren C, Wang D, Tan Q, Yang H, Li Y.
Esophagus. 2022 Jan;19(1):120-128. doi: 10.1007/s10388-021-00864-8. Epub 2021 Jul 28.
Long-term efficacy and progression patterns of paclitaxel plus cisplatin and 5-fluorouracil induction chemotherapy for locally advanced, borderline-resectable esophageal squamous cell carcinoma: results from a phase II NEOCRTEC1601 study.
Wu JD, Wang ZQ, Li QQ, Ren C, Huang S, Fang CY, Wang DS, Chen JY, Tan Q, Li YH, Yang H.
Int J Surg. 2025 May 1;111(5):3299-3305. doi: 10.1097/JS9.0000000000002360.
